Drug intelligence / Profile preview

MCT801

Development stage: Preclinical
Lead developer: Metacen Therapeutics
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics

Overview

MCT801 is a preclinical drug candidate being developed by Metacen Therapeutics for the treatment of Parkinson's disease. The asset is part of a pipeline that leverages proprietary technology platforms, specifically ABS Tech (Advanced Bio-System) and PBS Tech (Precision Bio-System), which focus on gut-brain axis integration. This approach aims to treat neurodegenerative diseases by modulating the communication between the gastrointestinal tract and the central nervous system. MCT801 is also being explored for Alzheimer's disease under the designation MCT801 AZ. As of early 2024, the program remains in the research and preclinical phase, and specific molecular targets have not been publicly disclosed.

Beyond the preview

Go deeper on MCT801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCT801.

Explore the full profile